Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Chen Yuan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0708-9648; OpenAlex author ID A5045483608, A5104110489; NIH RePORTER profile ID 78022911. Sources: OpenAlex.

Their work

Papers
42 (first author 5, last author 0)
Trials
0
Grants
1
Labs led
1
Collaborators
148
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 3 papers · 2017: 3 papers · 2018: 6 papers · 2019: 3 papers · 2020: 4 papers · 2021: 4 papers · 2022: 2 papers · 2023: 8 papers · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers, 1 grant

Papers 42

  1. Plasma cell-free DNA markers predict occult metastases in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.70573↗
  2. Risk of Pancreatic Cancer Associated With Precursor Lesions in Individuals and First-Degree Relatives: A Nationwide Cohort Study. Co-author DOI 10.1016/j.cgh.2026.06.009↗
  3. Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis. Co-author DOI 10.1093/jnci/djaf308↗
  4. Alcohol intake and pancreatic cancer risk: An analysis from 30 prospective studies across Asia, Australia, Europe, and North America. Co-author DOI 10.1371/journal.pmed.1004590↗
  5. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Co-author DOI 10.1136/gutjnl-2023-331074↗
  6. Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1164↗
  7. Pancreatic cancer is associated with medication changes prior to clinical diagnosis. Co-author DOI 10.1038/s41467-023-38088-2↗
  8. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Co-author DOI 10.1038/s41467-023-40024-3↗
  9. A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories. Co-author DOI 10.1038/s41591-023-02332-5↗
  10. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  11. Relationship between ABO Blood Group Alleles and Pancreatic Cancer Is Modulated by Secretor (FUT2) Genotype, but Not Lewis Antigen (FUT3) Genotype. First author DOI 10.1158/1055-9965.epi-23-0009↗
  12. Sex-Specific Associations between Adiponectin and Leptin Signaling and Pancreatic Cancer Survival. Co-author DOI 10.1158/1055-9965.epi-23-0505↗
  13. Oncogenic Drivers and Therapeutic Vulnerabilities in KRAS Wild-Type Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-3930↗
  14. Helicobacter pylori Seropositivity, ABO Blood Type, and Pancreatic Cancer Risk From 5 Prospective Cohorts. Co-author DOI 10.14309/ctg.0000000000000573↗
  15. The age-dependent association of risk factors with pancreatic cancer. Co-author DOI 10.1016/j.annonc.2022.03.276↗
  16. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  17. A 584 bp deletion in CTRB2 inhibits chymotrypsin B2 activity and secretion and confers risk of pancreatic cancer. Co-author DOI 10.1016/j.ajhg.2021.09.002↗
  18. Prediagnostic Inflammation and Pancreatic Cancer Survival. Co-author DOI 10.1093/jnci/djab040↗
  19. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  20. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Co-author DOI 10.1158/2159-8290.cd-20-0841↗
  21. Diabetes, Weight Change, and Pancreatic Cancer Risk. Co-author DOI 10.1001/jamaoncol.2020.2948↗
  22. A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Co-author DOI 10.1093/jnci/djz246↗
  23. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-19-1315↗
  24. Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population. First author DOI 10.1158/1055-9965.epi-19-1389↗
  25. Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. First author DOI 10.1038/s41416-019-0426-5↗
  26. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  27. Prediagnostic Leukocyte Telomere Length and Pancreatic Cancer Survival. First author DOI 10.1158/1055-9965.epi-19-0577↗
  28. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  29. Statin use and pancreatic cancer risk in two prospective cohort studies. Co-author DOI 10.1007/s00535-018-1430-x↗
  30. Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Co-author DOI 10.1016/j.cgh.2018.02.022↗
  31. Plasma inflammatory cytokines and survival of pancreatic cancer patients. Co-author DOI 10.1038/s41424-018-0008-5↗
  32. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Co-author DOI 10.1038/s41586-018-0235-7↗
  33. Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studie… First author DOI 10.1053/j.gastro.2017.12.001↗
  34. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Co-author DOI 10.1038/bjc.2017.349↗
  35. Leucocyte telomere length, genetic variants at the TERT gene region and risk of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-312510↗
  36. Cigarette Smoking and Pancreatic Cancer Survival. Co-author DOI 10.1200/jco.2016.71.2026↗
  37. Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. Co-author DOI 10.1093/jnci/djv409↗
  38. Pancreatic Cancer Risk Associated with Prediagnostic Plasma Levels of Leptin and Leptin Receptor Genetic Polymorphisms. Co-author DOI 10.1158/0008-5472.can-16-1699↗
  39. Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. Co-author DOI 10.1200/jco.2015.66.3005↗
  40. Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. Co-author DOI 10.1200/jco.2014.57.5688↗
  41. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Co-author DOI 10.1038/nm.3686↗
  42. Prediagnostic body mass index and pancreatic cancer survival. Co-author DOI 10.1200/jco.2013.51.7532↗

Grants 1

  1. Etiology and Tumor Characteristics of Early-onset Pancreatic Cancer K22CA288914↗

Closest collaborators

The 25 strongest of 148 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 38 shared papers, 2013–2026 · strength 3.66
  2. Kimmie Ng · 27 shared papers, 2013–2024 · strength 2.19
  3. Jonathan Andrew Nowak · 20 shared papers, 2017–2026 · strength 2.04
  4. Ana Babić · 23 shared papers, 2016–2024 · strength 1.91
  5. Peter Kraft · 22 shared papers, 2013–2023 · strength 1.83
  6. Charles S. Fuchs · 23 shared papers, 2014–2023 · strength 1.60
  7. Douglas Adam Rubinson · 21 shared papers, 2013–2024 · strength 1.50
  8. Edward L. Giovannucci · 20 shared papers, 2013–2023 · strength 1.49
  9. Vicente Morales‐Oyarvide · 19 shared papers, 2016–2023 · strength 1.35
  10. Qiao-Li Wang · 8 shared papers, 2022–2026 · strength 1.33
  11. Kimberly J. Perez · 11 shared papers, 2019–2024 · strength 1.20
  12. Andrew J. Aguirre · 11 shared papers, 2018–2024 · strength 1.13
  13. Thomas E. Clancy · 11 shared papers, 2015–2024 · strength 0.93
  14. Michael Hayden Rosenthal · 7 shared papers, 2018–2026 · strength 0.89
  15. JoAnn E. Manson · 12 shared papers, 2014–2023 · strength 0.87
  16. Natalia I. Khalaf · 11 shared papers, 2017–2023 · strength 0.83
  17. Jihye Kim · 5 shared papers, 2020–2023 · strength 0.70
  18. Alice A. Lee · 5 shared papers, 2022–2023 · strength 0.66
  19. Andressa Dias Costa · 6 shared papers, 2020–2024 · strength 0.63
  20. Zhi Rong Qian · 13 shared papers, 2013–2019 · strength 0.63
  21. Albert C. Koong · 8 shared papers, 2017–2023 · strength 0.60
  22. Laufey Thora Amundadottir · 7 shared papers, 2016–2023 · strength 0.59
  23. Richard Francis Dunne · 7 shared papers, 2017–2023 · strength 0.55
  24. Margaret M. Kozak · 7 shared papers, 2017–2023 · strength 0.55
  25. Daniel Tandel Chang · 7 shared papers, 2017–2023 · strength 0.55

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.